SCHEMBL16037699

SCHEMBL16037699

COC(=O)C1=C(c2ccc(Cl)cc2F)CC(C)(C)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 10/20 0.43
SLC6A2 P23975 5/20 0.42
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
BDKRB1 P46663 1/20 0.36
ABL1 P00519 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
CASP3 P42574 1/20 0.35
KMT2A Q03164 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
FASN P49327 1/20 0.35
ALPL P05186 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524482 0.80 SLC6A3 (0.63) SLC6A3SLC6A2MAPT
SCHEMBL16040021 0.79 SLC6A3 (0.52) SLC6A3SLC6A2
SCHEMBL31450116 0.78 SLC6A3 (0.41) SLC6A3SLC6A2ALDH1A1LMNAHTT
SCHEMBL16037793 0.75 PTGS2 (0.33) AKR1C3AKR1C2AKR1C1FASN
SCHEMBL16039916 0.75 FASN (0.35) AKR1C3AKR1C2AKR1C1FASN
SCHEMBL30075034 0.75 PTGS2 (0.33) AKR1C3AKR1C2AKR1C1FASN
SCHEMBL16037883 0.74 SLC6A3 (0.66) SLC6A3SLC6A2
SCHEMBL29750072 0.74 FASN (0.31) AKR1C3AKR1C2AKR1C1FASN
SCHEMBL29318559 0.73 PTGS2 (0.33) AKR1C3AKR1C2AKR1C1FASN
SCHEMBL29749709 0.73 FASN (0.31) AKR1C3AKR1C2AKR1C1FASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403467-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2021-12-30 US disclosed
CN-109641897-B Bcl-2 selective inhibitors, their preparation and use 北京赛林泰医药技术有限公司 2021-12-07 CN disclosed
CN-107987075-B Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维公司 2020-12-01 CN disclosed
US-20200331907-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2020-10-22 US disclosed
CN-109293656-A Bcl-2 selective depressant and its preparation and use 北京赛林泰医药技术有限公司 2019-02-01 CN disclosed
EP-3415514-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2018-12-19 EP disclosed
US-20180354952-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2018-12-13 US disclosed
US-10081628-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2018-09-25 US disclosed
EP-2970257-B1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2018-05-30 EP disclosed
WO-2018041248-A1 BCL-2 SELECTIVE INHIBITOR AND PREPARATION AND USE THEREOF 北京赛林泰医药技术有限公司 2018-03-08 WO disclosed
US-20170008891-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2017-01-12 US disclosed
EP-2970257-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2016-01-20 EP disclosed
US-20150299197-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2015-10-22 US disclosed
WO-2014158528-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2014-10-02 WO disclosed
US-20140275082-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2014-09-18 US disclosed